Is COGT or LKFT more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

$27.72 -0.43 (-1.53%)

As of 07/29/2026 04:00 PM Eastern

Compare

LKFT vs. RYTM, MIRM, LNTH, COGT, and PTCT

Should you buy Lakefront Biotherapeutics American Depositary Shares stock or one of its competitors? MarketBeat compares Lakefront Biotherapeutics American Depositary Shares with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lakefront Biotherapeutics American Depositary Shares include Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), Cogent Biosciences (COGT), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry.

How does Lakefront Biotherapeutics American Depositary Shares compare to Rhythm Pharmaceuticals?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.45	$363.05M	-$1.41	N/A
Rhythm Pharmaceuticals	$189.76M	38.47	-$196.54M	-$3.13	N/A

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $34.33, indicating a potential upside of 23.86%. Rhythm Pharmaceuticals has a consensus target price of $138.73, indicating a potential upside of 30.23%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.11
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Rhythm Pharmaceuticals had 11 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 15 mentions for Rhythm Pharmaceuticals and 4 mentions for Lakefront Biotherapeutics American Depositary Shares. Rhythm Pharmaceuticals' average media sentiment score of 1.21 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.98 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lakefront Biotherapeutics American Depositary Shares beats Rhythm Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Mirum Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

Mirum Pharmaceuticals currently has a consensus price target of $143.40, suggesting a potential upside of 33.64%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $34.33, suggesting a potential upside of 23.86%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Mirum Pharmaceuticals is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.11

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Mirum Pharmaceuticals. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.55	-$23.36M	-$13.61	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.45	$363.05M	-$1.41	N/A

In the previous week, Mirum Pharmaceuticals had 10 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 14 mentions for Mirum Pharmaceuticals and 4 mentions for Lakefront Biotherapeutics American Depositary Shares. Mirum Pharmaceuticals' average media sentiment score of 1.29 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.98 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mirum Pharmaceuticals beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Lakefront Biotherapeutics American Depositary Shares has lower revenue, but higher earnings than Lantheus. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.22	$233.56M	$4.15	24.10
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.45	$363.05M	-$1.41	N/A

Lantheus has a net margin of 18.05% compared to Lakefront Biotherapeutics American Depositary Shares' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Lakefront Biotherapeutics American Depositary Shares' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Lantheus has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

Lantheus currently has a consensus price target of $109.71, indicating a potential upside of 9.71%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $34.33, indicating a potential upside of 23.86%. Given Lakefront Biotherapeutics American Depositary Shares' higher possible upside, analysts clearly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.11

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lantheus had 11 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 15 mentions for Lantheus and 4 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.98 beat Lantheus' score of 0.70 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	6 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lantheus beats Lakefront Biotherapeutics American Depositary Shares on 11 of the 17 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cogent Biosciences has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

In the previous week, Cogent Biosciences had 8 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 12 mentions for Cogent Biosciences and 4 mentions for Lakefront Biotherapeutics American Depositary Shares. Cogent Biosciences' average media sentiment score of 1.60 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.98 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences presently has a consensus target price of $45.90, indicating a potential upside of 16.00%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $34.33, indicating a potential upside of 23.86%. Given Lakefront Biotherapeutics American Depositary Shares' higher possible upside, analysts plainly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.11

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Cogent Biosciences. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.45	$363.05M	-$1.41	N/A

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Summary

Cogent Biosciences beats Lakefront Biotherapeutics American Depositary Shares on 8 of the 15 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to PTC Therapeutics?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
PTC Therapeutics	-22.58%	-362.45%	-6.76%

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $34.33, indicating a potential upside of 23.86%. PTC Therapeutics has a consensus target price of $93.83, indicating a potential upside of 25.97%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe PTC Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.11
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.79

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

PTC Therapeutics has higher revenue and earnings than Lakefront Biotherapeutics American Depositary Shares. PTC Therapeutics is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.45	$363.05M	-$1.41	N/A
PTC Therapeutics	$1.73B	3.57	$682.64M	-$2.33	N/A

In the previous week, PTC Therapeutics had 9 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 13 mentions for PTC Therapeutics and 4 mentions for Lakefront Biotherapeutics American Depositary Shares. PTC Therapeutics' average media sentiment score of 1.00 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.98 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PTC Therapeutics beats Lakefront Biotherapeutics American Depositary Shares on 11 of the 17 factors compared between the two stocks.

Get Lakefront Biotherapeutics American Depositary Shares News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LKFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LKFT vs. The Competition

Export

Metric	Lakefront Biotherapeutics American Depositary Shares	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.86B	$3.74B	$7.08B	$12.15B
Dividend Yield	N/A	2.11%	2.65%	8.53%
P/E Ratio	-19.66	22.61	27.40	23.33
Price / Sales	1.45	301.37	521.07	86.08
Price / Cash	38.77	163.15	51.57	59.34
Price / Book	0.58	7.82	10.06	5.74
Net Income	$363.05M	$23.81M	$3.60B	$336.32M
7 Day Performance	-1.42%	-3.58%	-1.40%	-1.96%
1 Month Performance	-7.54%	-8.26%	-4.38%	-6.16%
1 Year Performance	-16.68%	35.02%	20.26%	13.66%

Lakefront Biotherapeutics American Depositary Shares Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LKFT Lakefront Biotherapeutics American Depositary Shares	2.2743 of 5 stars	$27.72 -1.5%	$34.33 +23.9%	-15.5%	$1.86B	$1.26B	N/A	1,310
RYTM Rhythm Pharmaceuticals	3.2486 of 5 stars	$106.26 +1.6%	$138.29 +30.1%	+24.4%	$7.29B	$189.76M	N/A	140	Positive News Upcoming Earnings Analyst Forecast
MIRM Mirum Pharmaceuticals	3.3829 of 5 stars	$116.98 +0.3%	$143.40 +22.6%	+109.7%	$7.13B	$521.31M	N/A	140	Positive News Upcoming Earnings Analyst Revision
LNTH Lantheus	3.3017 of 5 stars	$106.89 +2.4%	$110.43 +3.3%	+38.5%	$6.96B	$1.55B	25.76	1,193	News Coverage Upcoming Earnings Analyst Forecast
COGT Cogent Biosciences	2.1091 of 5 stars	$39.70 +3.7%	$45.90 +15.6%	+234.2%	$6.78B	N/A	N/A	80	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LKFT) was last updated on 7/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. RYTM, MIRM, LNTH, COGT, and PTCT

How does Lakefront Biotherapeutics American Depositary Shares compare to Rhythm Pharmaceuticals?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Lantheus?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Cogent Biosciences?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to PTC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. RYTM, MIRM, LNTH, COGT, and PTCT

How does Lakefront Biotherapeutics American Depositary Shares compare to Rhythm Pharmaceuticals?

Do insiders and institutionals hold more shares of LKFT or RYTM?

Which has better valuation and earnings, LKFT or RYTM?

Is LKFT or RYTM more profitable?

Which has more volatility & risk, LKFT or RYTM?

Do analysts prefer LKFT or RYTM?

Does the media favor LKFT or RYTM?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Is MIRM or LKFT more profitable?

Do institutionals and insiders have more ownership in MIRM or LKFT?

Which has more volatility and risk, MIRM or LKFT?

Do analysts recommend MIRM or LKFT?

Which has stronger earnings and valuation, MIRM or LKFT?

Does the media refer more to MIRM or LKFT?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Lantheus?

Which has better earnings & valuation, LNTH or LKFT?

Is LNTH or LKFT more profitable?

Which has more volatility & risk, LNTH or LKFT?

Do analysts prefer LNTH or LKFT?

Do insiders & institutionals have more ownership in LNTH or LKFT?

Does the media refer more to LNTH or LKFT?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Cogent Biosciences?

Do insiders and institutionals hold more shares of COGT or LKFT?

Which has more risk and volatility, COGT or LKFT?

Does the media refer more to COGT or LKFT?

Do analysts prefer COGT or LKFT?

Which has higher valuation & earnings, COGT or LKFT?

Is COGT or LKFT more profitable?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to PTC Therapeutics?

Is LKFT or PTCT more profitable?

Do analysts prefer LKFT or PTCT?

Do institutionals and insiders have more ownership in LKFT or PTCT?

Which has more volatility & risk, LKFT or PTCT?

Which has preferable valuation and earnings, LKFT or PTCT?

Does the media favor LKFT or PTCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools